Escient Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2018-05-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.escientpharma.com
An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Escient Pharmaceuticals, Inc
- Target Recruit Count
- 10
- Registration Number
- NCT06645704
- Locations
- 🇺🇸
Pharmaron Clinical Pharmacology Center (CPC), Baltimore, Maryland, United States
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Oral EP262Drug: Placebo
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Escient Pharmaceuticals, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT06144424
- Locations
- 🇺🇸
Dermatology Specialists of Spokane, Spokane, Washington, United States
🇺🇸Indiana Clinical Trials Center, Plainfield, Indiana, United States
🇺🇸J&S Studies, Inc., College Station, Texas, United States
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Drug: Oral EP262Drug: Placebo
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Escient Pharmaceuticals, Inc
- Target Recruit Count
- 113
- Registration Number
- NCT06077773
- Locations
- 🇺🇸
AllerVie Clinical Research, Birmingham, Alabama, United States
🇺🇸Scottsdale Clinical Trials, Scottsdale, Arizona, United States
🇺🇸University of South Florida, Tampa, Florida, United States
Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria
- Conditions
- Chronic Inducible Urticaria
- Interventions
- Drug: Oral EP262
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Escient Pharmaceuticals, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT06050928
- Locations
- 🇺🇸
Allergy & Asthma Specialists, P.S.C., Owensboro, Kentucky, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸National Allergy and Asthma Research, LLC., North Charleston, South Carolina, United States
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Escient Pharmaceuticals, Inc
- Target Recruit Count
- 62
- Registration Number
- NCT05525520
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸UPMC Center for Liver Disease, Pittsburgh, Pennsylvania, United States
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Escient Pharmaceuticals, Inc
- Target Recruit Count
- 89
- Registration Number
- NCT04510090
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
🇦🇺Monash Medical Centre, Clayton, Victoria, Australia
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia